Skip to search formSkip to main contentSkip to account menu

lymphokine-activated killer cell therapy

Known as: LAK cell therapy, cell therapy, lymphokine-activated killer, therapy, lymphokine-activated killer cell 
The use of lymphokine-activated killer cells in the treatment of any disease or disorder.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryInterleukin-1 (Il-1)-like activity in biological fluids was measured by their ability to rectify the Il-1-dependent… 
1992
1992
Pretreatment of acute myeloblastic leukemia cells with the hemopoietic growth factor interleukin 3 (IL3) increased their… 
1990
1990
Natural killer (NK) cells (CD3-) or large granular lymphocytes (LGL) spontaneously kill K562 targets but are unable to kill Daudi… 
Highly Cited
1989
Highly Cited
1989
The phenotype and function of lymphocytes from cancer patients treated with repetitive weekly cycles of continuous i.v. infusions… 
1989
1989
In this study 15 consecutive melanoma patients were treated with two courses of bolus recombinant interleukin 2 (rIL2) and rIL2… 
1989
1989
Killer helper factor (KHF) was previously found to be produced by a human T cell hybridoma, 24A CA2. We studied the therapeutic… 
1979
1979
Production of the lymphokine LIF (leukocyte migration inhibitory factor) by normal lymphocytes on stimulation with mitogens is…